CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Premiums earned, net (Net of ceded premiums of $470, $489, and $599 for the years ended December 31, 2022, 2021, and 2020, respectively)		$ 1,084,869	$ 799,414	$ 665,698
Non-Insurance revenue		2,380,135	667,639	0
Other income		11,683	4,943	7,190
Total revenues		3,476,687	1,471,996	672,888
Operating expenses:
Net medical claims incurred		3,453,952	1,551,178	590,082
Salaries and benefits		278,725	260,458	71,256
General and administrative expenses		207,917	185,287	120,830
Premium deficiency reserve (benefit) expense		(94,240)	110,628	(17,128)
Depreciation and amortization		1,187	1,246	555
Other expense		70	191	0
Total operating expenses		3,847,611	2,108,988	765,595
Loss from operations		(370,924)	(636,992)	(92,707)
Change in fair value of warrants		(900)	(66,146)	80,328
Interest expense		1,333	3,193	35,990
Amortization of notes and securities discounts		30	13,717	21,118
Gain on derivative		0	0	(93,751)
Gain on investment		(9,217)	0	0
Gain on extinguishment of note payable		(23,326)	0	0
Net loss		$ (338,844)	$ (587,756)	$ (136,392)
Per share data:
Net loss per share attributable to Class A and Class B common stockholders - basic (in dollars per share)	[1]	$ (0.71)	$ (1.42)	$ (1.54)
Net loss per share attributable to Class A and Class B common stockholders - diluted (in dollars per share)	[1]	$ (0.71)	$ (1.42)	$ (1.54)
Weighted average number of common shares outstanding
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	[1]	476,244,262	412,922,424	88,691,582
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	[1]	476,244,262	412,922,424	88,691,582
Net unrealized loss on available-for-sale investments		$ (7,440)	$ (1,944)	$ (36)
Comprehensive loss		$ (346,284)	$ (589,700)	$ (136,428)

[1] 2020 results have been adjusted to reflect the exchange of Legacy Clover's common stock for Clover Class B Common Stock at an exchange ratio of approximately 2.0681 in January 2021 as a result of the 2021 Business Combination. See Note 3 (Business Combination) for additional information. Because the Company had a Net loss during the years ended December 31, 2022, 2021, and 2020 the Company's potentially dilutive securities, which include stock options, restricted stock, preferred stock, and warrants to purchase shares of common stock and preferred stock, have been excluded from the computation of diluted net loss per share, as the effect would be anti-dilutive.